Bfsg LLC Buys Shares of 2,776 Embecta Corp. (NASDAQ:EMBC)

Bfsg LLC bought a new stake in Embecta Corp. (NASDAQ:EMBC) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,776 shares of the company’s stock, valued at approximately $53,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EMBC. River Road Asset Management LLC purchased a new position in Embecta in the third quarter valued at about $39,333,000. First Eagle Investment Management LLC purchased a new position in Embecta in the third quarter valued at about $7,308,000. Barclays PLC boosted its stake in Embecta by 917.4% in the third quarter. Barclays PLC now owns 533,905 shares of the company’s stock valued at $8,035,000 after acquiring an additional 481,426 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Embecta by 32.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 991,998 shares of the company’s stock valued at $14,930,000 after acquiring an additional 240,364 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Embecta by 641.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 193,873 shares of the company’s stock valued at $2,918,000 after acquiring an additional 167,732 shares during the last quarter. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

Embecta Stock Down 4.5 %

EMBC opened at $10.40 on Friday. The stock has a market cap of $598.83 million, a price-to-earnings ratio of 10.95 and a beta of 0.73. The company’s 50-day moving average price is $12.81 and its two-hundred day moving average price is $15.45. Embecta Corp. has a twelve month low of $9.93 and a twelve month high of $32.00.

Embecta (NASDAQ:EMBC) last announced its quarterly earnings results on Friday, February 9th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.15. The company had revenue of $277.30 million for the quarter, compared to analysts’ expectations of $264.92 million. Embecta had a net margin of 4.93% and a negative return on equity of 18.66%. Embecta’s revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.93 EPS. As a group, sell-side analysts anticipate that Embecta Corp. will post 2.14 earnings per share for the current year.

Embecta Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Wednesday, February 28th were paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 5.77%. The ex-dividend date of this dividend was Tuesday, February 27th. Embecta’s payout ratio is currently 63.16%.

Insider Activity at Embecta

In other Embecta news, Director David F. Melcher purchased 2,000 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were bought at an average cost of $16.25 per share, for a total transaction of $32,500.00. Following the purchase, the director now owns 45,080 shares of the company’s stock, valued at approximately $732,550. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.28% of the stock is currently owned by corporate insiders.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.